Maxim Group Downgrades Processa Pharmaceuticals (PCSA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PCSA Hot Sheet
Price: $1.92 -1.03%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Maxim Group analyst Naz Rahman downgraded Processa Pharmaceuticals (NASDAQ: PCSA) from Buy to Hold.
For an analyst ratings summary and ratings history on Processa Pharmaceuticals click here. For more ratings news on Processa Pharmaceuticals click here.
Shares of Processa Pharmaceuticals closed at $0.42 yesterday.
You May Also Be Interested In
- Processa Pharmaceuticals names four executives to leadership roles
- Lake Street Downgrades Flux Power Holdings (FLUX) to Hold
- Barclays Downgrades Driven Brands (DRVN) to Underweight
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
